Assessment of Sacsin Turnover in Patients With ARSACS: Implications for Molecular Diagnosis and Pathogenesis.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
07 12 2021
Historique:
received: 21 04 2021
accepted: 07 10 2021
pubmed: 16 10 2021
medline: 7 4 2022
entrez: 15 10 2021
Statut: ppublish

Résumé

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is caused by variations in We analyzed a large set of skin fibroblasts derived from patients with ARSACS, including both new and already published cases, carrying variations of different types affecting diverse domains of the protein. We found that sacsin is almost absent in patients with ARSACS, regardless of the nature of the variation. As expected, we did not detect sacsin in patients with truncating variations. We found it strikingly reduced or absent also in compound heterozygotes carrying diverse missense variations. In this case, we excluded Our results provide a mechanistic explanation for the lack of genotype-phenotype correlation in ARSACS. We also propose a new and unambiguous criterion for ARSACS diagnosis that is based on the evaluation of sacsin level. Last, we identified preemptive degradation of a mutant protein as a novel cause of a human disease.

Sections du résumé

BACKGROUND AND OBJECTIVES
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is caused by variations in
METHODS
We analyzed a large set of skin fibroblasts derived from patients with ARSACS, including both new and already published cases, carrying variations of different types affecting diverse domains of the protein.
RESULTS
We found that sacsin is almost absent in patients with ARSACS, regardless of the nature of the variation. As expected, we did not detect sacsin in patients with truncating variations. We found it strikingly reduced or absent also in compound heterozygotes carrying diverse missense variations. In this case, we excluded
DISCUSSION
Our results provide a mechanistic explanation for the lack of genotype-phenotype correlation in ARSACS. We also propose a new and unambiguous criterion for ARSACS diagnosis that is based on the evaluation of sacsin level. Last, we identified preemptive degradation of a mutant protein as a novel cause of a human disease.

Identifiants

pubmed: 34649874
pii: WNL.0000000000012962
doi: 10.1212/WNL.0000000000012962
pmc: PMC8665432
doi:

Substances chimiques

Heat-Shock Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2315-e2327

Informations de copyright

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Références

Orphanet J Rare Dis. 2018 Sep 19;13(1):165
pubmed: 30231904
Neurology. 2010 Sep 28;75(13):1181-8
pubmed: 20876471
Trends Biochem Sci. 2019 Nov;44(11):914-926
pubmed: 31301980
Biochim Biophys Acta Mol Cell Res. 2021 Jan;1868(1):118894
pubmed: 33091504
Biochimie. 2015 Jul;114:127-33
pubmed: 25701549
Mol Cell. 2013 Feb 7;49(3):411-21
pubmed: 23395271
Eur J Neurol. 2012 Aug;19(8):e77-8
pubmed: 22805644
Brain Sci. 2020 Dec 15;10(12):
pubmed: 33333791
Trends Biochem Sci. 2017 Jan;42(1):5-15
pubmed: 27746049
Genet Med. 2018 Dec;20(12):1528-1537
pubmed: 29790871
J Mol Neurosci. 2020 Jan;70(1):131-141
pubmed: 31701440
Mol Cell. 2013 May 9;50(3):368-78
pubmed: 23583076
Hum Mol Genet. 2015 Feb 1;24(3):727-39
pubmed: 25260547
J Biol Chem. 1998 Mar 27;273(13):7189-92
pubmed: 9516408
Cell. 2013 Jan 17;152(1-2):196-209
pubmed: 23332755
Neurol Neurochir Pol. 2017 Nov - Dec;51(6):481-485
pubmed: 28843771
J Biol Chem. 2011 Jun 10;286(23):20407-12
pubmed: 21507954
Hum Mol Genet. 2017 Aug 15;26(16):3130-3143
pubmed: 28535259
Neurogenetics. 2019 Mar;20(1):45-49
pubmed: 30680480
Orphanet J Rare Dis. 2013 Mar 15;8:41
pubmed: 23497566
N Engl J Med. 2017 Jan 5;376(1):21-31
pubmed: 27959697
Mol Cell. 2013 May 9;50(3):379-93
pubmed: 23583075
Nucleic Acids Res. 2014 Jan;42(Database issue):D859-64
pubmed: 24185699
Biomolecules. 2020 Jan 07;10(1):
pubmed: 31936054
Ann Neurol. 2015 Dec;78(6):871-86
pubmed: 26288984
Nat Commun. 2015 Sep 18;6:8261
pubmed: 26383020
Nat Genet. 2000 Feb;24(2):120-5
pubmed: 10655055
J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S33-8
pubmed: 24833584
Neurogenetics. 2009 Apr;10(2):151-5
pubmed: 19031088
Biochim Biophys Acta. 2010 Jul;1803(7):826-31
pubmed: 20359507
Mol Brain. 2019 Mar 12;12(1):19
pubmed: 30866998
Parkinsonism Relat Disord. 2011 Jul;17(6):418-22
pubmed: 21450511
Brain Res. 2020 Jan 1;1726:146459
pubmed: 31525351
Hum Mol Genet. 2009 May 1;18(9):1556-65
pubmed: 19208651
Can J Neurol Sci. 1978 Feb;5(1):61-9
pubmed: 647499
Hum Mol Genet. 2020 Jan 15;29(2):177-188
pubmed: 31868880
J Biol Chem. 1998 Sep 18;273(38):24649-53
pubmed: 9733761
Can J Neurol Sci. 2013 Jan;40(1):61-6
pubmed: 23250129
Hum Mutat. 2013 Mar;34(3):525-37
pubmed: 23280630
Cell. 2010 Mar 5;140(5):704-16
pubmed: 20211139
J Mol Biol. 2010 Jul 23;400(4):665-74
pubmed: 20488193

Auteurs

Fabiana Longo (F)

From the Mitochondrial Dysfunctions in Neurodegeneration Unit (F.L., D.D.R., D.F., F.M.) and Department of Neurology (M.S.), Ospedale San Raffaele, Milan, Italy; Istituto Nazionale di Genetica Molecolare (A.M., S.B.), INGM, "Romeo ed Enrica Invernizzi," Milan, Italy; Laboratory of Neuromuscular Pathology (J.B.), Institute Born-Bunge, University of Antwerp; Neuromuscular Reference Centre (J.B.), Department of Neurology, Antwerp University Hospital, Belgium; Molecular Medicine (F.M.S.), IRCCS Fondazione Stella Maris, Pisa, Italy; Department of Biosciences (S.B.), University of Milan; and Università Vita-Salute San Raffaele (F.M., D.D.R.), Milan, Italy.

Daniele De Ritis (D)

From the Mitochondrial Dysfunctions in Neurodegeneration Unit (F.L., D.D.R., D.F., F.M.) and Department of Neurology (M.S.), Ospedale San Raffaele, Milan, Italy; Istituto Nazionale di Genetica Molecolare (A.M., S.B.), INGM, "Romeo ed Enrica Invernizzi," Milan, Italy; Laboratory of Neuromuscular Pathology (J.B.), Institute Born-Bunge, University of Antwerp; Neuromuscular Reference Centre (J.B.), Department of Neurology, Antwerp University Hospital, Belgium; Molecular Medicine (F.M.S.), IRCCS Fondazione Stella Maris, Pisa, Italy; Department of Biosciences (S.B.), University of Milan; and Università Vita-Salute San Raffaele (F.M., D.D.R.), Milan, Italy.

Annarita Miluzio (A)

From the Mitochondrial Dysfunctions in Neurodegeneration Unit (F.L., D.D.R., D.F., F.M.) and Department of Neurology (M.S.), Ospedale San Raffaele, Milan, Italy; Istituto Nazionale di Genetica Molecolare (A.M., S.B.), INGM, "Romeo ed Enrica Invernizzi," Milan, Italy; Laboratory of Neuromuscular Pathology (J.B.), Institute Born-Bunge, University of Antwerp; Neuromuscular Reference Centre (J.B.), Department of Neurology, Antwerp University Hospital, Belgium; Molecular Medicine (F.M.S.), IRCCS Fondazione Stella Maris, Pisa, Italy; Department of Biosciences (S.B.), University of Milan; and Università Vita-Salute San Raffaele (F.M., D.D.R.), Milan, Italy.

Davide Fraticelli (D)

From the Mitochondrial Dysfunctions in Neurodegeneration Unit (F.L., D.D.R., D.F., F.M.) and Department of Neurology (M.S.), Ospedale San Raffaele, Milan, Italy; Istituto Nazionale di Genetica Molecolare (A.M., S.B.), INGM, "Romeo ed Enrica Invernizzi," Milan, Italy; Laboratory of Neuromuscular Pathology (J.B.), Institute Born-Bunge, University of Antwerp; Neuromuscular Reference Centre (J.B.), Department of Neurology, Antwerp University Hospital, Belgium; Molecular Medicine (F.M.S.), IRCCS Fondazione Stella Maris, Pisa, Italy; Department of Biosciences (S.B.), University of Milan; and Università Vita-Salute San Raffaele (F.M., D.D.R.), Milan, Italy.

Jonathan Baets (J)

From the Mitochondrial Dysfunctions in Neurodegeneration Unit (F.L., D.D.R., D.F., F.M.) and Department of Neurology (M.S.), Ospedale San Raffaele, Milan, Italy; Istituto Nazionale di Genetica Molecolare (A.M., S.B.), INGM, "Romeo ed Enrica Invernizzi," Milan, Italy; Laboratory of Neuromuscular Pathology (J.B.), Institute Born-Bunge, University of Antwerp; Neuromuscular Reference Centre (J.B.), Department of Neurology, Antwerp University Hospital, Belgium; Molecular Medicine (F.M.S.), IRCCS Fondazione Stella Maris, Pisa, Italy; Department of Biosciences (S.B.), University of Milan; and Università Vita-Salute San Raffaele (F.M., D.D.R.), Milan, Italy.

Marina Scarlato (M)

From the Mitochondrial Dysfunctions in Neurodegeneration Unit (F.L., D.D.R., D.F., F.M.) and Department of Neurology (M.S.), Ospedale San Raffaele, Milan, Italy; Istituto Nazionale di Genetica Molecolare (A.M., S.B.), INGM, "Romeo ed Enrica Invernizzi," Milan, Italy; Laboratory of Neuromuscular Pathology (J.B.), Institute Born-Bunge, University of Antwerp; Neuromuscular Reference Centre (J.B.), Department of Neurology, Antwerp University Hospital, Belgium; Molecular Medicine (F.M.S.), IRCCS Fondazione Stella Maris, Pisa, Italy; Department of Biosciences (S.B.), University of Milan; and Università Vita-Salute San Raffaele (F.M., D.D.R.), Milan, Italy.

Filippo M Santorelli (FM)

From the Mitochondrial Dysfunctions in Neurodegeneration Unit (F.L., D.D.R., D.F., F.M.) and Department of Neurology (M.S.), Ospedale San Raffaele, Milan, Italy; Istituto Nazionale di Genetica Molecolare (A.M., S.B.), INGM, "Romeo ed Enrica Invernizzi," Milan, Italy; Laboratory of Neuromuscular Pathology (J.B.), Institute Born-Bunge, University of Antwerp; Neuromuscular Reference Centre (J.B.), Department of Neurology, Antwerp University Hospital, Belgium; Molecular Medicine (F.M.S.), IRCCS Fondazione Stella Maris, Pisa, Italy; Department of Biosciences (S.B.), University of Milan; and Università Vita-Salute San Raffaele (F.M., D.D.R.), Milan, Italy.

Stefano Biffo (S)

From the Mitochondrial Dysfunctions in Neurodegeneration Unit (F.L., D.D.R., D.F., F.M.) and Department of Neurology (M.S.), Ospedale San Raffaele, Milan, Italy; Istituto Nazionale di Genetica Molecolare (A.M., S.B.), INGM, "Romeo ed Enrica Invernizzi," Milan, Italy; Laboratory of Neuromuscular Pathology (J.B.), Institute Born-Bunge, University of Antwerp; Neuromuscular Reference Centre (J.B.), Department of Neurology, Antwerp University Hospital, Belgium; Molecular Medicine (F.M.S.), IRCCS Fondazione Stella Maris, Pisa, Italy; Department of Biosciences (S.B.), University of Milan; and Università Vita-Salute San Raffaele (F.M., D.D.R.), Milan, Italy.

Francesca Maltecca (F)

From the Mitochondrial Dysfunctions in Neurodegeneration Unit (F.L., D.D.R., D.F., F.M.) and Department of Neurology (M.S.), Ospedale San Raffaele, Milan, Italy; Istituto Nazionale di Genetica Molecolare (A.M., S.B.), INGM, "Romeo ed Enrica Invernizzi," Milan, Italy; Laboratory of Neuromuscular Pathology (J.B.), Institute Born-Bunge, University of Antwerp; Neuromuscular Reference Centre (J.B.), Department of Neurology, Antwerp University Hospital, Belgium; Molecular Medicine (F.M.S.), IRCCS Fondazione Stella Maris, Pisa, Italy; Department of Biosciences (S.B.), University of Milan; and Università Vita-Salute San Raffaele (F.M., D.D.R.), Milan, Italy. maltecca.francesca@hsr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH